These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Pantelis C; Adesanya A Aust N Z J Psychiatry; 2001 Aug; 35(4):544-5. PubMed ID: 11531743 [No Abstract] [Full Text] [Related]
9. Valproate-induced pseudoatrophy: expanding the clinical and imaging spectrum. Lovett M; Skidmore DL; Mohamed IS Pediatr Neurol; 2014 Aug; 51(2):284-5. PubMed ID: 25079580 [No Abstract] [Full Text] [Related]
10. Valproate-induced hyperammonemia as a cause of altered mental status. Feil D; Chuang K; Sultzer DL Am J Geriatr Psychiatry; 2002; 10(4):476-8. PubMed ID: 12095907 [TBL] [Abstract][Full Text] [Related]
11. Incidence of Neutropenia With Valproate and Quetiapine Combination Treatment in Subjects With Acquired Brain Injuries. Park HJ; Kim JY Arch Phys Med Rehabil; 2016 Feb; 97(2):183-8. PubMed ID: 26427579 [TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity and valproate therapy. Betrosian A; Frantzeskaki F Intern Med J; 2006 Nov; 36(11):752-4. PubMed ID: 17040368 [No Abstract] [Full Text] [Related]
13. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Rahman A; Mican LM; Fischer C; Campbell AH Ann Pharmacother; 2009 May; 43(5):822-30. PubMed ID: 19401471 [TBL] [Abstract][Full Text] [Related]
14. Unusual cutaneous reaction with sodium valproate. Roy S; Goel D Neurol India; 2009; 57(2):216-7. PubMed ID: 19439862 [No Abstract] [Full Text] [Related]